Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Olaparib (Lynparza, AstraZeneca) with bevacizumab (Avastin, Roche) is indicated for the 'maintenance treatment of adult patients with advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency positive status defined by either a BRCA1/2 mutation and/or genomic instability'.

The dosage schedules are available in the summary of product characteristics for olaparib and the summary of product characteristics for bevacizumab.

The list price for olaparib tablets is £2,317.50 per 14‑day pack (56×150‑mg tablets) or £4,635.00 per 28‑day cycle (excluding VAT; BNF online, accessed May 2023).

The company has a commercial arrangement. This makes olaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.